Germantown biotech Orgenesis will expand its Baltimore footprint with a new subsidiary, Morgensis, that will be based in the city and focus on manufacturing cell therapies for other companies and startups.
Morgenesis will be located at the Maryland Center for Cell Therapy Manufacturing, a 7,000-square-foot facility the company is building with Johns Hopkins Medicine at its East Baltimore medical campus. To spur the creation of the subsidiary, New York private equity firm Metalmark Capital gave Morgenesis…
